BETHEL, Conn., Jan. 15, 2008 (PRIME NEWSWIRE) -- Aduromed Industries, Inc. (OTCBB:ADRM) a leading manufacturer of medical waste treatment systems, today announced the sale of another MC4 Series system to its partner ARAMARK. This MedClean(r) system will be installed at a hospital site in Southern California and is expected to treat approximately 650,000 pounds of medical waste annually. The system will be installed as part of an expansion and upgrade project at the hospital and will replace an existing competitor's technology that had been in use at this institution since 1997. This most recent sale represents the seventh facility in Southern California to choose the MedClean Series solution from Aduromed.
"Our continued growth in the competitive environment of Southern California is evidence of the value our MedClean system brings to each Aduromed client," said Damien R. Tanaka, CEO and President of Aduromed. "The Southern California market was early to adopt on-site treatment, and our replacement of previously installed competitor's equipment demonstrates that this facility understood and appreciated the enhanced benefits of our superior technology."
The new installation of the MC4 Series system also shows the continued progress for the waste stream management program designed by ARAMARK, known as the WasteStream QL program initiative, which features Aduromed's MedClean System.
About Aduromed:
Aduromed Industries, Inc., through its wholly-owned subsidiary, Aduromed Corporation, is a provider of innovative systems for the onsite treatment and disposal of regulated medical waste. Aduromed's flagship MedClean(r) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste.
Aduromed was founded in 1997 with corporate headquarters, research and development and distribution facilities located in Bethel, Connecticut. Further information on Aduromed can be found at www.aduromed.com and in filings with the Securities and Exchange Commission found at www.sec.gov.
Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-KSB for the year ended December 31, 2006, filed with the SEC on March 30, 2007, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.